Nov 12, 2021 - 13th Profile from Germany: ADOReg
ADOReg is a nationwide German prospective registry for health services research in dermatologic oncology. The skin cancer registry ADOReg was developed by ADO and ONKODATAMED GmbH working in collaboration - in 2014. The data come from skin cancer treating sites (59 as of 2021) which treat ~8,500 patients, who have one of the following types of skin cancer:
- Malignant Melanoma
ADOReg / DeCOG (Germany)
Database Contact Data
Do you have a general request or a specific inquiry? Please feel free to contact ADOREG staff by sending an e-mail to
office@adoscience.org, or you may call them at the following phone numbers in Germany:
Phone: +49 030 322932913
Alternate Contact
Prof. Dr. med. Michael Weichenthal
Department of Dermatology, Venerology and Allergology
University Skin Clinic Kiel
Arnold-Heller-Str.3
24105 Kiel
Phone: +49 0431 500 21141
Email: mweichthal@dermatology.uni-kiel.de
References of Studies Using/Describing Database
1. Lodde G, Dollani J, Galetzka W, Mohr P, Meier F, Gutzmer R, Weichenthal M, Utikal J, Herbst R, Leiter U, Pföhler C. Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma. British Journal of Dermatology. 2026 May;194(5):843-53.
2. Kostev K, Rodemer I, Alymova S, Konrad M. Factors associated with the likelihood of being diagnosed with stage I melanoma in Germany: a multicenter study on 12 648 patients from the ADOReg skin cancer registry. European Journal of Cancer Prevention. 2026 Mar 1;35(2):166-72.
3. Lallas K, Nanz L, Ugurel S, Mohr P, Meier F, Weichenthal M, Von Wasielewski I, Terheyden P, Hassel J, Kreuter A, Herbst R. Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG. European journal of cancer. 2026 Feb 20:116582.
4. Geidel G, Bänsch S, Adam L, Fekade N, Rünger A, Zell T, Smit DJ, Kött J, Heidrich I, Weichenthal M, Ugurel S. Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis. Journal of the European Academy of Dermatology and Venereology. 2026.
5. Zimmermann N, Kött J, Meiss F, Gebhardt C. Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment–Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg. European journal of cancer. 2026;234:116195.
6. Leven AS, Peters T, Rajcsanyi LS, Weichenthal M, Mohr P, Meier F, von Wasielewski I, Gutzmer R, Utikal J, Terheyden P, Herbst R. Sex-specific survival in advanced metastatic melanoma–a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG. European Journal of Cancer. 2025 Jul 29:115668.
7. DeTemple VK, Kaatz M, Stockfleth E, Scheel C, Angela Y, Gutzmer R, Leiter U, Meier F, Schadendorf D, Livingstone E, Gebhardt C. Real-world experience with first-versus second-line cemiplimab for advanced basal cell carcinoma. European Journal of Cancer. 2025 Jul 25;225:115590.
8. Jiang R, Weichenthal M, Fernandez-Lazaro CI, Rudolph A, Krepler C, Mohr P. HSR24-154: Real-World Clinical Outcomes in Patients With Advanced/Metastatic Melanoma and Brain Metastases Treated With Pembrolizumab Monotherapy—An Analysis of the ADOReg German Skin Cancer Registry. Journal of the National Comprehensive Cancer Network. 2024 Apr 5;22(2.5).
9. Kochanek C, Gilde C, Zimmer L, Ugurel S, Meier F, Utikal J, Pföhler C, Herbst R, Haferkamp S, Welzel J, Dücker P, Leiter U, Weichenthal M, von Wasielewski I, Angela Y, Gutzmer R. Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG. Eur J Cancer. 2024 Feb;198:113508.
10. Franklin C, Mohr P, Bluhm L, Meier F, Garzarolli M, Weichenthal M, Kähler K, Grimmelmann I, Gutzmer R, Utikal J, Terheyden P, Herbst R, Haferkamp S, Pfoehler C, Forschner A, Leiter U, Ziller F, Meiss F, Ulrich J, Kreuter A, Gebhardt C, Welzel J, Schilling B, Kaatz M, Scharfetter-Kochanek K, Dippel E, Nashan D, Sachse M, Weishaupt C, Löffler H, Gambichler T, Loquai C, Heinzerling L, Grabbe S, Debus D, Schley G, Hassel JC, Weyandt G, Trommer M, Lodde G, Placke JM, Zimmer L, Livingstone E, Becker JC, Horn S, Schadendorf D, Ugurel S. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. J Immunother Cancer. 2023 Apr;11(4):e005828. doi: 10.1136/jitc-2022-005828. Erratum in: J Immunother Cancer. 2024 Jan 31;12(1).
Nov 2, 2021 – Newest EMR profile from the USA
The Tempus N & ASCO/CancerLinQ® is a longitudinal population database covering over 25% of all cancer patients in the US and utilizes electronic medical records for Biological Modeling, Next-generation sequencing (NGS)/Pathology, Real World Data Aggregation & Analytics (standard and bespoke); and Technology applications (Custom and Machine Learning) embedded into its platform.
Tempus (USA)
Database Contact Data
Matt Love
VP, Business Development
Tempus
USA
Phone: +1 (610) 458-7021 (Office)
Phone: +1 (610) 220-0047 (Cell)
Email: matt.love@tempus.com
Alternate Contact
Contact Tempus by completing the contact form at: https://www.tempus.com/contact-us/
References of Studies Using/Describing Database
Tempus has made the decision not to directly publish but to supply the data to publish for its partners. Many publications have been authored by these partners. Please contact Tempus for details.